

#### EXPRESS MAIL NO.: <u>EV 452 773 871 US</u>

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Kunz et al.

Confirmation No.:

1690

Application No.:

09/910,388

Art Unit:

1653

Filed:

July 20, 2001

Examiner:

Robinson, Hope A.

For:

THERAPEUTIC INHIBITOR

Attorney Docket No.:

10177-211-999

OF VASCULAR SMOOTH

(CAM 008563-999208)

**MUSCLE CELLS** 

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the United States Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be related to patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references A01-A08, B01-B79 and C01-C184 listed on the accompanying List of References Cited by Applicants. Copies of references B75-B79, C01 and C03-C184 are submitted herewith. Copies of references A01-A08 and B01-B74 are being concurrently submitted under separate cover with Express Mail No. EV 452 774 381 US.

The above-identified application claims priority under 35 U.S.C. § 120 to U.S. Patent Application No. 09/113,733 ("the '733 application"), filed July 10, 1998, now U.S. Patent No. 6,074,659, issued June 13, 2000. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of the '626 application for copies of reference C02.

References B01-B06, B08, B12-B15, B18, B22-B27, B34-B37, B39-B41, B42-B45, B47-B49, B51, B53-B72, B74-B79, C01-C11, C13-C31, C33, C36-C45, C47-C70, C73-C76,

C78-C88, C90-C103, C105-C118, C120-C127, C129-C163, C165-C171 and C173-C184 were previously cited in the Information Disclosure Statement filed on July 20, 2001, the Supplemental Information Disclosure Statement filed on January 25, 2002, the Supplemental Information Disclosure Statement filed on March 25, 2002, and the Supplemental Information Disclosure Statement filed on June 26, 2002 and are allegedly missing from the files of the application. References A01-A08, B07, B09-B11, B16-B17, B19-B21, B28-B33, B38, B42, B46, B50, B52, B73, C12, C32, C34-C35, C46, C71-C72, C77, C89, C104, C119, C128, C164 and C172 were recently brought to the attention of Attorneys for Applicants.

Identification of the above-listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 CFR § 1.97(b), since this Supplemental Information Disclosure

Statement is being filed before the mailing date of a first Office Action on the merits, it is
believed that no fee is due in connection herewith. However, should the United States Patent
and Trademark Office determine otherwise, please charge the required fee to Jones Day

Deposit Account No. 50-3013.

Respectfully submitted,

Date: November 22, 2004

Gidon D. Stern

27,469

By:

Catharina J. Chin Eng

42,412

JONES DAY

222 East 41<sup>st</sup> Street

(Reg. No.)

New York, New York 10017

(212) 326-3939

**Enclosures** 



EP 0 365 863

B03

LIST OF REFERENCES CITED BY APPLICANTS

(Use several sheets if necessary)

#### **EXPRESS MAIL NO.: EV 452 773 871 US**

Sheet 1 of 9

ATTY DOCKET NO. 10177-211-999

(Cam No. 008563-999208)

APPLICATION NO

09/910,388

APPLICANT

Kunz et al.

FILING DATE July 20, 2001 GROUP 1653

**U.S. PATENT DOCUMENTS** 

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
	A01	4,391,797	07/05/83	Folkman et al.			
	A02	4,768,507	09/06/88	Fischell et al.			
	A03	5,019,096	05/28/91	Fox et al.			-
	A04	5,474,563	12/12/95	Myler et al.			
	A05	5,512,055	04/30/96	Domb et al.			
	A06	5,567,417	10/22/96	Sasisekharan et al.			
	A07	5,616,608	04/01/97	Kinsella et al.			
	A08	6,403,635 B1	06/11/02	Kinsella et al.			

		FOREIG	N PATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	NO
B01	EP 0 260 066	03/16/88	European				
B02	EP 0 297 946	01/04/89	European	1	1		

European

05/02/90

B04	EP 0 374 044	06/20/90	European			
· B05	EP 0 411 893	02/06/91	European			
B06	EP 0 451 202	10/16/91	European			
. B07	EP 0 470 569 A1	08/06/91	European		-	
B08	EP 0 526 102	02/03/93	European	ĺ		
B09	EP 0 543 653 A1	05/26/93	European			
B10	EP 0 567 816 A1	04/08/93	European			
B11	EP 0 568 310 A1	04/27/93	European			
B12	EP 0 577 215	01/05/93	European			
B13	EP 0 588 518	03/23/94	European			
B14	EP 0 606 613	07/20/94	European		-	
B15	EP 0 622 076	11/02/94	European			
B16	EP 0 623 354 A1	11/09/94	European			
B17	EP 0 623 354 B1	10/02/02	European			
B18	EP 0 691 130	01/10/96	European			
B19	EP·0-7·1-1-1·58-B·1-	-12/03/03	-European-			
B20	EP 1 181 943 A1	02/27/02	European			
B21	WO 85/00107	01/17/85	PCT	ļ		
B22	WO 88/10259	12/29/88	PCT			

## **EXPRESS MAIL NO.:** <u>EV 452 773 871 US</u> Sheet 2 of 9

	<u> </u>	WO 90/01969	03/08/90	PCT				
<u> </u>	323	WO 90/11676	10/18/90	PCT				
	324	WO 90/11070 WO 90/12597	11/01/90	PCT				
	325	WO 90/13293	11/01/90	PCT				
<del></del>	326	WO 90/13293	11/15/90	PCT				-
	327	WO 91/07154	05/30/91	PCT				
<b>-</b>	328							
	329	WO 91/10424	07/25/91	PCT				
<u> </u>	330	WO 91/11193	08/08/91	PCT				
	331	WO 91/12779	09/05/91	PCT				
	332	WO 91/12846	09/05/91	PCT				
В	333	WO 91/15219	10/14/91	PCT				
В	334	WO 91/15222	10/17/91	PCT				
В	335	WO 91/17731	11/28/91	PCT				
В	336	WO 92/08480	05/29/92	PCT				
В	337	WO 92/10210	06/25/92	PCT				
В	338	WO 92/11872	07/23/92	PCT				
В	339	WO 92/11890	07/23/92	PCT				
В	340	WO 92/11895	07/23/92	PCT				
В	341	WO 92/12717	08/06/92	PCT				
В	342	WO 92/15286	02/21/02	PCT				
В	343	WO 92/18546	10/29/92	PCT				
В	344	WO 92/19273	11/12/92	PCT				
B	345	WO 92/21363	12/10/92	PCT				
B	346	WO 93/06792	04/15/93	PCT				
B	347	WO 93/07748	04/29/93	PCT				
B	348	WO 93/09790	05/27/93	PCT				
В	349	WO 93/11120	06/10/93	PCT				
· B	350	WO 93/16687	09/02/93	PCT				
E	351	WO 93/17121	09/02/93	PCT				
· B	352	WO 93/17669	09/16/93	PCT				
Е	353	WO 93/24476	12/09/93	PCT				
E	354	WO 94/03644	02/17/94	PCT				
В	355	WO 94/04164	03/03/94	PCT				
В	356	WO 94/04178	03/03/94	PCT				
В	357	WO 94/07529	04/14/94	PCT				
E	358	WO 94/08604	04/28/94	PCT				
E	359	WO 94/08605	04/28/94	PCT				
E	360	WO 94/15590	07/21/94	PCT				
Е	361	WO 94/15646	07/21/94	PCT				
E	362	WO 94/16706	08/04/94	PCT				
E	363	WO 94/17786	08/18/94	PCT			-	
E	364	WO 94/18345	08/18/94	-PCT-		-		
E	365	WO 94/18954	09/01/94	PCT				
E	366	WO 94/18967	09/01/94	PCT	Ī -			
B	367	WO 94/18968	09/01/04	PCT		<u> </u>	_	
						<u> </u>	L	L

B68	WO 94/19000	09/01/94	PCT	
B69	WO 94/19001	09/01/94	PCT	_
B70	WO 94/19003	09/01/94	PCT	
B71	WO 94/20096	09/25/94	PCT	
B72	WO 94/20097	09/15/94	PCT	
B73	WO 94/21308	09/29/94	PCT	
B74	WO 94/21679	09/29/94	PCT	
B75	WO 94/22436	10/13/94	PCT	
B76	WO 94/25020	11/10/94	PCT	
B77	WO 94/28721	12/22/94	PCT	
B78	WO 95/03036	02/02/95	PCT	
B79	WO 95/03795	02/02/95	PCT	

	•	
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
	C01	"Cytochalasins", In: The Merck Index, Eleventh Edition, Merck & Co., Rahway NJ, 438-439 (1989).
	C02	"Nolvadex Tamoxifene Citrate", ICI Pharma, 64033-02, Rev L/07/92
,	C03	Allemann, et al., "Drug Loaded Poly(Lactic Acid) Nanoparticles Produced by a Reversible Salting-out Process: Purification of an Injectable Dosage Form," Eur. J. Pharm. Biopharm., Vol. 39 (1), pp. 13-18 (1993)
	C04	Anderson, et al., "Effects of Acetate Dialysate on Transforming Growth Factor $\beta_1$ Interleukin, and $\beta_2$ -Microglobulin Plasma Levels," Kidney International, Vol. 40, pp. 1110-1117 (1991)
	C05	Aschermann, M., "Restenosis After Percutaneous Transluminal Coronary Angioplasty Pathophysiology, New Trends in Prevention and Treatment," Cor. Vasa., 36:211-218 (1994)
	C06	Assoian, et al., "Type β Transforming Growth Factor in Human Platelets: Release During Platelet Degranulation and Action on Vascular Smooth Muscle Cells," The Journal of Cell Biology, Vol. 102, pp. 1217-1223 (1986)
	C07	Attwood, et al., "A Light Scattering Study on Oil-in-Water Microemulsions" Int'l J. Pharm, 52 165-171 (1989)
	C08	Bagdade, et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition," J. of Clinical Endocrinology and Metabolism, Vol. 70, No. 4, pp. 1132-35 (1990)
	C09	Bamburg, James R., "Biological and Biochemical Actions of Trichothecene Mycotoxins," <i>Progress in Molecular and Subcellular Biology</i> ", (Hahn F.E., et al., ed.), Springer-Verlag, pp. 41-110) (1983)
	C10	Barath, et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury," JACC, Vol. 13, No. 2, p. 252A Abstract (1989)
	C11	Barbacid, et al., "Binding of [acetyl-14 C] Trichodermin to the Peptidyl Transferase Center of Eukaryotic Ribosomes," Eur. J. Biochem. 44, pp. 437-444 (1974)
-	C12	Bartoli et al. "In vitro and in vivo antitumoral activity of free, and encapsulated taxol". J. Microencapsulation, 7 (2):191-197, 1990
	C13	Beck, et al., "Poly(DL-Lactide-co-glycolide) /Norethisterone Microcapsules: An Injectable Biodegradable Contraceptive," Biology of Reproduction, Vol. 28, pp. 186-195 (1983)
	C14	Bertelli, et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels," Breast Cancer Res. and Treatment, Vol. 12, pp. 307-310 (1988)
	C15	Bogyo, et al., "Cytochalasin-β-Induced Immunosuppression of Murine Allogeneic Anti-tumor Response and the Effect of Recombinant Human Interleukin-2," Cancer Immunol. Immunother, Vol. 32, pp. 400-405 (1991)
	C16	Bousquet, et al., "Effects of Cytochalasin β in Culture and in Vivo on Murine Madison 109 Lung Carcinoma and on B16 Melanoma," Cancer Res., Vol. 50, pp. 1431-39 (1990)
	C17	Bruengger, et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steroid Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs," J. Urol. Vol. 130, No. 6, pp. 1208-10 (1983)
	C18	Bruning, et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", Br. J. Cancer, 58, 497-499 (1988)
	C19	Bumol, et al., "Unique Glycoprotein-Proteoglycan Complex Defined by Monoclonal Antibody on Human Melanoma Cells," PNAS (USA), Vol. 79, pp. 1245-49 (1982)
	. C20_	Butta, et al., "Induction of Transforming Growth Factor β <sub>1</sub> in Human Breast Cancer in vivo Following Tamoxifen Treatment," Cancer Res. Vol. 52, pp. 4261-64 (1992)
	C21	Casscells, W., et al., "Elimination of Smooth Muscle Cells in Experimental Restenosis: Targeting of Fibroblast Growth Factor Receptors", Proc. Natl. Acad. Sci. USA, 89, 7159-7163 (1992)
	C22	Chaldakov, et al., "Cyclic AMP-and Cytochalasin B-induced Arborization in Cultured Aortic Smooth Muscle Cells: Its Cytopharmacological Characterization," Cell Tissue Res. Vol. 255, pp. 435-442 (1989)

	C23	Chander, et al., "Pyrrolidino-4-iodotamoxifen and 4-lodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer," Cancer Research, Vol. 51, pp. 5851-5858 (1991)
	C24	Chao, et al., "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome," Cytokine, Vol. 3, No. 4, pp. 292-298 (1991)
	C25	Chapman, et al., "A Bioabsorbable Stent: Initial Experimental Results," Supplement III Cir., Vol. 82, No. 4, p.
	C25	III-72 (1990)
	C26	Clowes et al., "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery," Cir. Res.
		Vol. 56, No. 1, pp. 139-145 (1985)
	C27	Clowes, et al. "Mechanisms of Stenosis After Arterial Injury", Laboratory Investigation, Vol. 49, No. 2, pp. 208-215 (1983)
	C28	Clowes, et al., "Kinetics of Cellular Proliferation After Arterial Injury - I. Smooth Muscle Growth in the Absence of Endothelium", Laboratory Investigation, Vol. 49, No. 3, pp. 327-333 (1983)
	C29	Clowes, et al., "Kinetics of Cellular Proliferation After Arterial Injury - III, Endothelial and Smooth Muscle Growth in Chronically Denuded Vessels", Laboratory Investigation, Vol. 54, No. 3, pp. 295-303 (1986)
	C30	Cohen, et al., "Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres," Pharmaceutical Research, Vol. 8, No. 6, pp. 713-720 (1991)
	C31	Cole, R. J. et al., "The Cytochalasins", In: Handbook of Toxic Fungal Metabolics, Academic Press, New York, p. 264-265, 281-282 (1981)
	C32	Coomber and Gotlieb "In vitro endothelial wound repair. Interaction of cell migration and proliferation".  Ateriosclerosis, 10 (2):215-222, 1990
	C33	Cowsar, et al., "Poly(Lactide-co-glycolide) Microcapsules for Controlled Release of Steroids," Methods in Enzymology, Vol. 112, pp. 101-117 (1985)
	C34	Cox et al., "Effects of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries". Coronary Artery Disease, 3:237-248, 1992
	C35	Cox et al., "Local Delivery of Heperin and methotrexate fails to inhibit in vivo smooth muscle cell proliferation". Circulation Suppl. 84(4):II-71, #0284, 1991
	C36	Crissman, et al., "Transformed Mammalian Cells are Deficient in Kinase-Mediated Control of Progression Through the G <sub>1</sub> Phase of the Cell Cycle," PNAS (USA), Vol. 88, pp. 7580-84 (1991)
	C37	Danielpour, David, "Improved Sandwich Enzyme-Linked Immunosorbent Assays for Transforming Growth Factor," Journal of Immunological Methods, Vol. 158, pp. 17-25 (1993)
	C38	Danielpour, et al., "Evidence for Differential Regulator of TGF\(\beta\)1 and TGF\(\beta\)2 Expression in Vivo by Sandwich
	C36	Enzyme-linked Immunosorbent Assays," Annals New York Academy of Sciences, pp. 300-302
	C39	Danielpour, et al., "Immunodetection and Quantitation of the Two Forms of Transforming Growth Factor-Beta
		(TGF-1 and TGF-2) Secreted by Cells in Culture," Journal of Cellular Physiology, Vol. 138, pp. 79-86 (1989)
	C40	Dasch, et al., "Capture Immunoassays Specific for TGF1 and TGF2: Use in Pharmacokinetic Studies," Annals
		New York Academy of Sciences, pp. 303-305
	C41	Detre, et al., "Percutaneous Transluminal Coronary Angioplasty in 1985-1986 and 1977-1981", The New England J. of Med., Vol 318, No. 5, pp. 265-270 (1988)
	C42	Dimond, Patricia F., Ph.D., "TGF-Beta Shows Potential as Therapeutic Agent for Macular Holes," Genetic Engineering News, pp. 7 & 19 (1993)
·	C43	Ebner, et al., "Cloning of a Type 1 TGF-β Receptor and Its Effect on TGF-β Binding to the Type II Receptor,"  Science, Vol. 260, pp. 1344-48 (1993)
	C44	Eldridge, et al., "Biodegradable and Biocompatible Poly(DL-Lactide-CO-Glycolide) Microspheres as an
	<del></del>	Adjuvant for Staphylococcal Enterotoxin B Toxoid which Enhances the Level of Toxin-Neutralizing
		Antibodies," Infection and Immunity, 59(9):2978-2986 (1991)
	C45	Epstein, Stephen E., MD., "Cytotoxic Effects of a Recombinant Chimeric Toxin on Rapidly Proliferating Vascular Smooth Muscle Cells," Cir. Vol. 84, No. 2, pp. 778-787 (1991)
	C46	Ettenson and Gotlieb "Centrosomes, Microtubules, and Microfilaments in the Reendothelialization and
į	C10	Remodeling of Double-Sided In Vitro Wounds". Laboratory Investigation, Vol. 68, No. 6, pp. 722-733, 1992,
		United States and Canadian Academy of Pathology, Inc.
	C47	Fanelli, et al., "Restenosis Following Coronary Angioplasty", Amer. Heart J., Vol 119, No. 2, Part 1, pp. 357-368 (1990)
	C48	Farhat, et al., "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium," Br. J. Pharmacol. Vol. 107, pp. 679-683 (1992)
	C49	Faxon et al., "Restenosis Following Transluminal Angioplasty in Experimental Atherosclerosis", Arteriosclerosis, Vol. 4, No. 3, pp. 189-195 (1984)
	C50	Fay, et al., "Effects of Cytochalasin B-On-The-Uptake of Ascorbic Acid and Glucose By-3T3 Fibroblasts:
		Mechanism of Impaired Ascorbate Transport in Diabetes," Life Sci., Vol. 46, pp. 619-624 (1990) (USA)
	C51	Feelisch, et al., "Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and
		Endothelial Cells," Biochemical and Biophysical Research Communications, Vol. 180, No. 1, pp. 286-293 (1991)
		[\1771]

	<u>`</u>	·
	C52	Fischer, et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis Experimental and Molecular Pathology", Exp. Mol. Pathol., 43 288-296 (1985)
	C53	Forrester, J.S., et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies: JACC, 17, 758-769, (1991)
	C54	Friberg, et al., "Microemulsions and Solubilization by Nonionic Surfactants", Prog. Colloid and Polymer Sci., 56, 16-20 (1975)
	C55	Fulop, et al., "Age-Dependent Variations of Intralysosomal Enzyme Release from Human PMN Leukocytes Under Various Stimuli," Immunobiol., Vol. 171, pp. 302-310 (1986)
	C56	Garrigues, et al., "The Melanoma Proteoglycan: Restricted Expression on Microspikes, a Specific Microdomain of the Cell Surface," J. Cell Biol. Vol. 103, pp 1699-1710 (1986)
	C57	Gasco, et al., "In Vitro Permeation of Azelaic Acid from Viscosized Microemulsions", International Journal of
	C58	Pharmaceutics, 69, 193-196 (1991)  Gasco, M. R., et al., "Long-acting Delivery Systems for Peptides: Reduced Plasma Testosterone Levels in Male
	C59	Rats after a Single Injection:, Intl. J. of Pharmaceut, 62 119-123 (1990)  Glagov, et al., "Compensatory Enlargement of Human Atherosclerotic Coronary Arteries," New England J. of
	C60	Med., Vol. 316 No. 22, p. 1371-1375 (1987)  Goldman, et al., "Influence of Pressure on Permeability of Normal and Diseased Muscular Arteries to
	C61	Horseradish Peroxidase," Atherosclerosis, Vol. 65, pp, 215-225 (1987) Grainger, et al., "Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing
	C62	transforming growth factor-like activity from serum," Cardiovascular Research, Vol 27, pp. 2238-47 (1993) Grainger, et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells in
	C63	Culture by Inducing Production of Transforming Growth Factor β," Biochem J. Vol. 294, pp. 109-112 (1993) Grainger, et al., A Large Accumulation of Non-Muscle Myosin Occurs at First Entry into M Phase in Rat
	C64	Vascular Smooth-Muscle Cells," <i>Biochem. J.</i> Vol. 277, pp. 145-151 (1991) Grainger, <i>et al.</i> , Hexamethylenebisacetamide Selectively Inhibits the Proliferation of Human and Rat Vascular
	C65	Smooth Muscle Cells," <i>Biochem. J.</i> Vol. 283, p. 403-408 (1992)  Gregory, <i>et al.</i> "Effects of Treatment with Cyclosporine, FK 506, Rapamycin, Mycophenolic Acid, or
	C66	Deoxyspergualin on Vascular Muscle Proliferation in Vivo," Transplantation Proceedings, 25:770-771 (1993)  Hanke, et al., Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-
	C67	Weight Heparin," Circulation, Vol 85, No. 4, pp. 1548-56 (1992)  Harpel, et al., "Plasmin Catalyzes Binding of Lipoprotein (α) to Immobilized Fibrinogen and Fibrin," Proc. Natl.
	C68	Acad. Sci. USA, Vol. 86, pp. 3847-3851 (1989)  Heldin, et al., "Demonstration of an Antibody Against Platelet-derived Growth Factor," Experimental Cell
		Research, "Vol. 136, pp. 255-261 (1981)  Heller, et al., "Preparation of Polyacetals by the Reaction of Divinyl Ethers and Polyols," J. of Polymer Science:
	C69	Polymer Letters Edition, Vol. 18, pp. 298-297 (1980)
<b>├─</b> √───┼	C70 C71	Henriksson, et al., "Hormonal Regulation of Serum Lp (α) Levels; J. Clin. Invest. Vol. 89, p. 1166-1171 (1992)  Hermans et al., "Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a
		"magic bullet" American Heart Journal, 122 (1) Part, 1, 171-187, 1991  Hirata et al., "Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-
	C72	dose methotrexate". Arthritis and Reumatism, 32(9): 1065-1073, 1989
	C73	Hoff, et al., "Modification of Low Density Lipoprotein with 4-Hydroxynonenal Induces Uptake by Macrophages," Arteriosclerosis, Vol. 9, No. 4, pp. 538-549 (1989)
	C74	Hoffman, et al., "Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C," Int. J. Cancer, Vol. 42, pp. 382-388 (1988)
	C75	Holland, et al., "Atherogenic Levels of Low-density Lipoprotein Increase Endocytotic Activity in Cultured Human Endothelial Cells," Amer. J. of Pathology, Vol. 140, No. 3, pp. 551-558 (1992)
	C76	Hwang et al., "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1 and TGF-B) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture." Exp. Cell Res., 200, 358-360 (1992)
	C77	Jampel et al., "In vitro release of hydrophobic drugs from polyanhydride disks". Ophthal Surg, 23 (11):676-680, 1991
	C78	Jarvis, et al., "Allelopathic Agents from Parthenium hysterophorus and Baccharis megapotamica," Chemistry of Alleopathy, pp. 149-159 (1985)
	C79	Jarvis, et al., "Macrocylic and Other Novel Trichothecenes: Their Structure, Synthesis, and Biological Significance," Acc. Chem. Res. 15 pp. 338-395 (1982)
	C80	Johnson, et al., "Coronary Atherectomy: Light Microscopic and Immunochemical Study of Excised Tissues," Supp. II Circulation, Vol. 78, No. 4, p. II-82 (1988)
	C81	Jordan, V. Craig, "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept to Clinical Trials," Hormones, Cell Biol. and Cancer: Perspectives and Potentials, pp. 105-123 (1988)
	C82	Jung, S.M., et al., "Platelet Cytoskeletal Protein Distributions in Two Triton-Insoluble Fractions and How They are Affected by Stimulants and Reagents that Modify Cytoskeletal Protein Interactions" Thrombosis Research,
·		

	1	
		50 775-787 (1988)
-	C83	Kambic, et al., "Biomaterials in Artificial Organs," Chemical & Engineering News, pp. 31-48 (1986)
	C84	Kemp et al., "The Id Gene is Activated by Serum But is Not Required for De-differentiation in Rat Vascular Smooth Muscle Cells," Biochem. J. (Great Britain), Vol. 277, pp. 285-288 (1991)
_	C85	Knabbe, C., et al., "Evidence That Transforming Growth Factor beta is a Hormonally Regulated Negative Growth Factor in Human Breast Cancer Cells" Cell, 48 417-428
	C86	Koff, et al., "Negative Regulation of GI in Mammalian Cells: Inhibition of Cyclin E-Dependent Kinase by TGF-β, Science, Vol. 260, pp. 536-538 (1993)
	C87	Kovach, et al., "Serial Intravascular Ultrasound Studies Indicate That Chronic Recoil Is An Important Mechanism Of Restenosis Following Transcatheter Therapy," JACC Vol. 484A, Abstract 835-3 (1993)
	C88	LaFont, et al., "Post-angioplasty Restenosis In The Atherosclerotic Rabbit: Proliferative Response Or Chronic Constriction?," Circulation, Vol. 88, I-521, Abstract 2806 (1993)
	C89	Lambert et al., "A new method for arterial drug delivery via removable stent". JACC, 21(2):483A, #834-2, 1992
	C90	Lambert, et al., "Local Drug Delivery Catheters: Functional Comparison of Porous and Microporous Designs," Coronary Artery Disease, Vol. 4, No. 5, pp. 469-475 (1993)
	C91	Lefer, Allen M., "Role of Transforming Growth Factor β in Cardioprotection of the Ischemic-Reperfused Myocardium," <i>Growth Factors and the Cardiovascular System</i> , Chapter 14 (Cummins, P. ed.), Kluwer Academic Publishers, pp. 249-260 (1993)
	C92	Lefer, et al., "Mechanism of the Cardioprotective Effect of Transforming Growth Factor β <sub>1</sub> , in Feline Myocardial Ischemia and Reperfusion," PNAS (USA), Vol. 90, pp. 1018-22 (1993)
	C93	Lefer, et al., "Mediation of Cardioprotection by Transforming Growth Factor-β," Science, Vol. 249, pp. 61-64 (1990)
	C94	Levy, "Drug Release from Submicronized O/W Emulsion: A New In Vitro Kinetic Evaluation Model", Intl. J. Pharmaceut., 66, 29-37 (1990)
	C95	Levy, et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants," Chemical Abstracts, 121, 580: Abstract No. 263625g (1994)
	C96	Li, et al., "Structure and Dynamics of Microemulsions which Mimic the Lipid Phase of Low-Density Lipoproteins", Biochimica et Biophysica Acta, 1042, 42-50 (1990)
	C97	Liaw, et al., "Osteopontin Promotes Vascular Cell Adhesion and Spreading and Is Chemotactic for Smooth Muscle Cells In Vitro," Cir. Res. Vol. 74, No. 2, pp. 214-224 (1994)
	C98	Lin, et al., "Expression Cloning of the TGF-β Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase," Cell. Vol. 68, pp. 775-785 (1992)
	C99	Linn, et al., "Microemulsion for Intradermal Delivery of Cetyl Alcohol and Octyl Dimethyl Paba", Drug Development and Industrial Pharmacy, 16, 899-920
	C100	Intraperitoneal Bolus Administration In Mice," Analytical Biochem., Vol. 161, pp. 332-340 (1987)
•	C101	Liu, et al., "Restenosis After Coronary Angioplasty - Potential Biologic Determinants and Role of Intimal Hyperplasia," Circulation, Vol. 79, No. 6, pp. 1374-87 (1989)
•	C102	Internal Medicine, Vol. 115, No. 11, pp. 860-864 (1991)
	C103	Node-Negative Breast Cancer," J. of the National Cancer Institute, Vol. 82, No. 16, pp. 1327-32 (1990)
	C104	TiPS- Nov. 1990 [Vol. 11]
	C105	Malcolmson, et al., "A Comparison Between Nonionic Micelles and Microemulsions as a Means of Incorporating the Poorly Water Soluble Drug Diazepam", J. Pharm. Pharmacol, 42 6p, (1990)
	C106	No. 2, pp. 308-312 (1972)
	C107	Mang, Tien-Dung Duc, "Distribution to Normal and Tumor Tissues of Cytochalasin B After Intravenous Administration in Mice," Thesis Submitted for Honors B.S. in Biology, Syracuse University
	C108	(1990)
	C109	Transforming Growth FactMacroglobulin Inactive Complex," The J. of Cell Biology, Vol. 109, pp. 441-448 (1989)
	C110	McCarroll, et al., "Preliminary Studies on the Regulation of Secretion of Latent Transforming Growth Factor-β [(TGF-β)] by Endothelial Cells in Culture, Clin. Chem. Vol. 36, No. 6, pp. 1-152-(1990)-Abstract-No. 0934-
	CIII	McCormick, et al., "Retinoid-Tamoxifen Interaction in Mammary Cancer Chemoprevention," Carcinogenesis, Vol. 7, No. 2, pp. 193-196 (1986)
	C112	McDonald, et al., "Fatal Myocardial Infarction in the Scottish Adjuvant Tamoxifen Trial," BMJ, Vol. 303 pp. 435-437 (1991)

CH	
011	330, No. 6143, pp. 132-137 (1987)  McQuiggan, James Daniel: "Tissue Distribution of Cytochalasin B After Intraperitoneal Bolus and
C114	Microencapsulated Injection in Mice and its Effect on β-N-Acetylglucosaminidase Activity in Cultured B16-
	BL6 Melanoma Cells," Thesis Submitted in partial fulfillment of the requirements for the degree of Master of
	Science in Biology in the Graduate School of Syracuse University, published Syracuse University, Biology
	Dept. (1988)
C115	Vasc. Res., Vol. 29, pp. 376-384 (1992)
C116	38, No. 18, pp. 3093-3102 (1989)
C117	More et al., "A Targeted Antithrobotic Conjugate with Antiplatelet and Fibrinolytic Properties which reduces in vivo Thrombus Formation", Cardiovascular Research, 27, 2200-2204 (1993).
C118	Morisaki, et al., "Effects of Transforming Growth Factor β on Growth of Aortic Smooth Muscle Cells,"  Atherosclerosis, Vol. 88, pp. 227-234 (1991)
C119	77 171 77 171 77 171 77 171 771 771 771
C120	Nabel, "Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall", Science, 244, 1342-1344 (1983)
C121	The state of the s
C122	N. 1 (0.1) D. 1 (0.1) C. 125 1 (1.1) C. 125 1
C123	
C124	
C125	
	Specimens: Clues to Lesion Calcification," Cir. Vol. 88, p. I-619, Abstracts from the 66 <sup>th</sup> Scientific Sessions (1993)
C126	O'Connor-McCourt, et al., "Latent Transforming Growth Factor β in Serum: A Specific Complex with 2- Macroglobulin," The Journal of biological Chemistry, Vol. 262, No. 29, pp. 14090-14099 (1987)
C127	01 1 7 (700 0 077070 1 7 1 7 1 7 1 7 1 7 1 7 1 7
C128	O-Keefe Jr. et al., "Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty".  JACC, 19(7): 1597-1600, 1992
C129	Oliveira, et al., "Isolation and Characterization of Smooth Muscle Cell Membranes," Biochimica et Biophysica Acta. Vol. 332, pp. 221-232 (1974)
C130	Osborne, et al., "Microemulsions as Topical Drug Delivery Vehicles: In Vitro Trandermal Studies of a Model Hydrophilic Drug", J. Pharm. Pharmacol., 43, 451-454 (1991).
C131	<u> </u>
C132	Palmaz et al., "Intravascular Stents", Advances in Vascular Surgery, 1, 107-135 (1993).
C133	Pardee, et al., "Control of Cell Proliferation," Cancer, Vol. 39, pp. 2747-54 (June Supplement 1977)
C134	
C135	
C136	
C137	The state of the s
C138	The state of the s
C139	
C140	
C141	
C142	Reid, et al., "Fragmentation of DNA in P388D <sub>1</sub> Macrophages Exposed to Oxidized Low-density Lipoprotein,"
C143	FEBS Letters, Vol. 332, No. 3, pp. 218-220 (1993) Ross, et al., "Chronic Inflammation, PDGF, TGF, and Smooth Muscle Proliferation, Abstracts from the 20 <sup>th</sup>
L	NYJD: 1553707.2

_		Annual Meeting of the Keystone Symposia on Molecular Biology, Session on Molecular Mechanisms of Vascular Disease, J. Cell Biochem. S15C, Abstract No. G006, p. 96 (1991)
· · · · · · · · · · · · · · · · · · ·	C144	Ross, Russell, "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s, <i>Nature</i> , Vol. 362, pp. 801-09 (1993)
	C145	Sagitani, et al., "Microemulsion Systems with a Nonionic Cosurfant" J. Dispersion Science and Technology, 1 (2), 151-164 (1980)
	C146	Sanders, et al., "Controlled Release of a Luteinizing Hormone-Releasing Hormone Analogue from Poly(d,l-lactide-co-glycolide) Microspheres," <i>Journal of Pharmaceutical Sciences</i> , Vol. 73, No. 9, pp. 1294-1297 (1984) Schatz, "A View of Vascular Stents", Circulation, 79 445-457 (1989)
	C147	
	C148	Schlingemann, et al., Expression of the High Molecular Weight Melanoma-Associated Antigen by Pericytes During Angiogenesis in Tumors and in Healing Wounds," Amer. J. Pathology, Vol. 136, No. 6, pp. 1393-1405 (1990)
	C149	Schneiderman, et al., "Increased Type I Plasminogen Activator Inhibitor Gene Expression in Atherosclerotic Human Arteries," PNAS (USA), Vol. 89, pp. 6998-7002 (1992)
	C150	CT
	C151	Arteries, Circulation, Vol. 82, No. 6, pp. 2190-2200 (1990)
	C152	
	C153	Shananhan, et al., "Isolation of Gene Markers of Differentiated and Proliferating Vascular Smooth Muscle Cells," Circulation Research, Vol. 73, No. 1 (1993)
	C154	1345 (1992)
	C155	Lipid Microspheres," J. Pharm. Pharmacol. 38:118-121 (1985)
	C156	No. 0326, p. II-82, (1988)
	C157	of Cell Biology, Vol. 95, pp. 667-671 (1982)
	C158	Smooth Muscle Cells," American J. of Pathology, Vol. 137, No. 2 (1990)
	C159	265, 391-394 (1994)
	C160	Model", Circulation Research, 57 105-112 (1985)
•	C161	Streuli, et al., "Extracellular Matrix Regulators Expression of the TGF-β1 Gene," The J. of Cell Biol. Vol. 120, No. 1, pp. 253-260 (1993)
		Suckling, Keith E., "Emerging Strategies for the Treatment of Atherosclerosis as Seen from the Patent Literature," <i>Biochem. Society Transactions</i> , Vol. 21, pp. 660-662 (1993)
	C163	Tamm, Ch. Basel, "The Antibiotic Complex of the Verrucarins and Roridins," Fortschr. Chem. Org. Naturst., 31:65 117 (1974)
	C164	Tang et al., "Regression of collagen-induced arthritis with taxol, a microtubule stabilizer". Arthritis and Rheumatism, 36 (9) Suppl.:S45, 1993
	C165	Tice, et al., "Biodegradable controlled-release parental systems" Pharmaceutical Technology, 26-35 (1984)
	C166	Topol, Eric J., "The Restenosis "Antitheory", Mayo Clinic Proc. Vol. 68, pp. 88-90 (1993)
	C167	Vanhoutte, P.M., "Hypercholesterolemia, Atherosclerosis And Release Of Endothelium-Derived Relaxing Factor By Aggregating Platelets," <i>European Heart J.</i> Vol. 12, Supplement E. pp. 25-32 (1991)
	C168	Vargas, et al., "Oestradiol Inhibits Smooth Muscle Cell Proliferation of Pig Coronary Artery," Br. J. Pharmacol., Vol. 109, pp. 612-617 (1993)
	C169	THE RESERVE TO SERVE THE PARTY OF THE PARTY
	C170	Foam Cells from Rabbit Atherosclerotic Lesions," J. Clin. Invest. Vol. 91, pp. 1011-18 (1993)
	C171	Voisard, et al., "The In-Vitro Effect of Antineoplastic Agents on Proliferative Activity and Cytoskeletal Components of Plaque-derived Smooth-muscle Cells from Human Coronary Arteries," Coronary Artery
	C172	Disease, 4:935-942 (1993)  Voisard, R., et al., "Search for new strategies for prevention of restenosis after angioplasty: the effect of cytostatic drugs on cell migration of re-stenosing human plaques cells in vitro". Vasa Suppl. 1992; 35: 132-3 [Article in German]

# **EXPRESS MAIL NO.: EV 452 773 871 US**Sheet 9 of 9

C173	Wakefield, et al., "Latent Transforming Growth Factor β from Human Platelets: A High Molecular Weight Complex Containing Precursor Sequences," The Journal of Biological Chemistry, Vol. 263, No. 16, pp. 7646-
	7654 (1988)
C174	Wakefield, et al., "Recombinant Latent Transforming Growth Factor I Has a Longer Plasma Half-Life in Rats than Active Transforming Growth Factor, I, and a Different Tissue Distribution," The Journal of Clinical Investigation, Inc., Vol. 86, pp. 1976-1984 (1990)
C175	Weissberg, et al., "Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation," Cardiovascular Res., Vol. 27, pp. 1191-98 (1993)
 C176	Platelet-Derived Growth Factor for Vascular Smooth Muscle Cells," <i>Atherosclerosis</i> , Vol. 85, pp. 257-262 (1990)
C177	Weissberg, et al., Effects of TGFB on Vascular Smooth Muscle Cell Growth, Growth Factors and the Cardiovascular System, (Cummins, P.ed), Kluwer Academic Publishers, p. 189-205 (1993)
 C178	Wight, et al., "Proteoglycans Structure and Function," Cell Biol. of Extracellular Matrix, Second Edition, edited by Elizabeth D. Hay, PLENUM PRESS, NEW YORK CHAPTER 2, pp. 45-78 (1991)
C179	Wight, et al., "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation," Current Opinion in Cell Biol. Vol. 4, pp. 793-801 (1992)
 C180	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 C181	Wilensky, et al., "Direct Intraarterial Wall Injection of Microparticles via a Catheter: A Potential Drug Delivery Strategy Following Angioplasty," American Heart Journal, Vol. 122, No. 4, pp. 1136-1140 (1991)
C182	Wolinsky, et al., "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery, JACC, Vol. 15, No. 2, pp. 475-81 (1990)
C183	Zuckerman, et al., "Cytokine Regulation of Macrophage apo E Secretion: Opposing Effects of GM-CSF and TGF-β," Atherosclerosis, Vol. 96, pp. 203-214 (1992)
 C184	Zukerman, et al., "Exogenous Glucocorticoids Increase Macrophage Secretion of E by Cholesterol-Independent Pathways," Atherosclerosis, Vol. 103, pp. 43-54 (1993)

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)				

EXAMINER	DATE CONSIDERED		
`			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.